The House of Commons Health Committee: ‘The Influence of the Pharmaceutical Industry’ – too much too late?

Aaron C , Lincoln T (2003) The other drug war. Drug companies deploy an army of 675 lobbyists to protect profits. Washington DC Public Citizen Congress Watch, June

Angell M (2004) Excess in the pharmaceutical industry. Canadian Medical Association Journal 12: 1451–1463

Clarkson K W (1996) The effects of research and promotion on rates of return. In Helms R B (ed.), Competitive Strategies in the Pharmaceutical Industry. American Enterprise Institute, Washington DC, pp. 238–268

Fortune 500 (2004) How the industries stack up. Fortune 149: F26-F26

Frech H E III , Miller R D Jr (1999) Productivity of Health Care and Pharmaceuticals. American Enterprise Institute, Washington DC

Government's Response to the Health Committee's Report on the Influence of the Pharmaceutical Industry (2005) Her Majesty's Stationery Office, London

Healy D (2003) In the grip of the python: conflicts at the university industry interface. Science Engineering and Ethics 9: 59–71

Henry J Kaiser Family Foundation (2004) Prescription drug trends – a chart book update. The Foundation 2001, p. 45-45, available online at: www.keff.org

House of Commons Health Committee (2005) The influence of the Pharmaceutical Industry. Fourth report of session, 2004–2005. The Stationery Office Limited, London

Moncrieff J (2006) Psychiatric drug promotion and the politics of neoliberalism. British Journal of Psychiatry 188: 301–302

Stano M (2000) Regulating the pharmaceutical industry: who really benefits? American Journal of Managed Care 6: 29–31

Tengs T O , Adams M E , Pliskin J S (1995) Five hundred life saving interventions and their cost-effectiveness. Risk analysis 15: 369–390